Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA)

Historical Holders from Q3 2020 to Q1 2025

Symbol
TSHA on Nasdaq
CUSIP
877619106
Type / Class
Equity / Common Stock, par value $0.00001 per share
Shares outstanding
210M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
167M
Holdings value
$289M
% of all portfolios
0.001%
Grand Portfolio weight change
+0%
Number of holders
125
Number of buys
66
Number of sells
-42
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MORGAN STANLEY 8.6% $24.5M 17.6M Morgan Stanley Dec 31, 2024
FMR LLC 8% $22.7M 16.4M FMR LLC Dec 31, 2024
RTW INVESTMENTS, LP 5.9% $17.2M 12.4M RTW Investments, LP Dec 31, 2024
Octagon Capital Advisors LP 5.1% $14.5M 10.5M Octagon Capital Advisors LP Dec 31, 2024

Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 247K $343K -$30.6K $1.39 5
2024 Q4 167M $289M +$19M $1.73 125
2024 Q3 157M $315M -$17.6M $2.01 114
2024 Q2 158M $354M +$33.9M $2.24 102
2024 Q1 140M $402M +$19.2M $2.87 105
2023 Q4 130M $230M -$12.4M $1.77 85
2023 Q3 130M $410M +$376M $3.16 61
2023 Q2 13.7M $9.05M -$2.01M $0.66 37
2023 Q1 16.7M $13.3M -$3.03M $0.80 42
2022 Q4 19.4M $43.8M +$11.9M $2.26 51
2022 Q3 12.9M $25M -$1.79M $1.93 47
2022 Q2 14.6M $54.4M -$11.1M $3.72 53
2022 Q1 16.8M $110M -$16.4M $6.52 68
2021 Q4 18.3M $213M -$15.5M $11.65 60
2021 Q3 19.4M $362M +$2.74M $18.62 48
2021 Q2 18.3M $388M +$15M $21.20 48
2021 Q1 17.7M $359M -$11.6M $20.30 46
2020 Q4 16.9M $447M +$34.1M $26.54 49
2020 Q3 16.6M $367M +$367M $22.40 46